🌐Read in
മലയാളം தமிழ் मराठी বাংলা ಕನ್ನಡ తెలుగు ગુજરાતી ਪੰਜਾਬੀ हिन्दी

Zydus Lifesciences Ltd: ₹96,166 Crore in Market Cap, But Still Prescribing Growth Pills

1. At a Glance

Zydus Lifesciences (a.k.a. the artist formerly known as Cadila Healthcare) is a ₹96,166 crore pharmaceutical heavyweight with operations spanning generics, branded formulations, vaccines, and biosimilars. They just dropped their Q1 FY26 results: revenue ₹6,574 Cr (+6% YoY), PAT ₹1,467 Cr (+3% YoY). International markets are driving growth, USFDA approvals keep coming in, and acquisitions like Amplitude Surgical hint at a more aggressive global expansion. Stock trades at ₹956 with a P/E of ~20.6 — basically, not dirt cheap but not in “bubble pharma” territory either.

2. Introduction

Imagine a company that can treat your fever, make your blood pressure behave, and still have time to launch an arthritis implant business in France — that’s Zydus. Born out of the Cadila split in 1995, it’s grown from ₹250 Cr turnover to ₹23,608 Cr in TTM sales.

FY25 was a blockbuster with ₹4,673 Cr profit, but the stock tanked 24% over the year — because Mr. Market has the attention span of a caffeinated squirrel. The Q1 FY26 numbers show steady but not jaw-dropping growth, proving that even pharma giants need new product pipelines to keep investors hooked.

3. Business Model (WTF Do They Even Do?)

  • Generics: Bread-and-butter revenue from the US, India, and emerging markets.
  • Specialty & Biosimilars: Higher-margin portfolio including injectables and biotech products.
  • Consumer Wellness: Brands like Sugar Free, EverYuth, and Nutralite.
  • Animal Health: Because even your dog needs a prescription sometimes.

Diversification is their defensive moat — if one market sneezes, another is already selling the tissues.

4. Financials Overview

  • TTM Revenue: ₹23,608 Cr
  • TTM EBITDA: ₹7,063 Cr (EBITDA margin ~30%)
  • TTM PAT: ₹4,711 Cr (Net Margin ~20%)
  • Q1 FY26 Revenue: ₹6,574 Cr (+6% YoY)
  • Q1 FY26 PAT: ₹1,467 Cr (+3% YoY)

P/E Recalculation:
Q1 EPS = ₹14.58 ⇒ Annualized EPS ≈ ₹58.3
CMP ₹956 ⇒ Adjusted P/E ≈ 16.4 (cheaper than reported because of annualization).

Commentary: Profitability is strong, margins are fat, and debt is under control — pharma investors call this “investment grade candy”.

5. Valuation (Fair Value Range)

MethodCalculationFV (₹)
P/E MethodEPS ₹55–58 × P/E 18–20990–1,160
EV/EBITDAEBITDA ₹7,063 Cr × 12–13 EV/EBITDA – Net Debt ₹(Negative)1,050–1,150
DCF (10% WACC, 6% growth)Based on 5-yr projections1,000–1,150

Fair Value Range: ₹990 – ₹1,150

This FV range is for educational purposes only and is not investment advice.

6. What’s Cooking – News, Triggers, Drama

  • Q1 FY26: Modest growth but solid margins.
  • USFDA approvals
Read Full Article Here
Become a member

Leave a Reply

FII & DII Data | Institutional Money Tracker

FII & DII Data

Institutional Money Flow Tracker | by Mr. Chartist
LOCAL ARCHIVE (Mar 13)
Latest Trading Session
Friday, 13 March 2026
Aggressive Selling
FII / FPI NET
-₹10,724 Cr
DII NET
+₹9,977 Cr
FII Aggression: 52% DII Support: 48%
Combined Liquidity -₹747 Cr
Current FII Streak
—
Streak Volume
—
5-Day FII Net Velocity
—
Computing…
FII 5-Yr Cumulative
-₹11.01L Cr
Historical allocation extraction
DII 5-Yr Cumulative
+₹20.45L Cr
The domestic fortress
SIP Monthly Run-Rate
₹26,500 Cr
Retail structural backbone
FII NSE500 Ownership
16.1%
Down from 28% peak

Derivatives Positioning (F&O)

Participant-wise Open Interest Analysis
—
FOREIGN INSTITUTIONAL INVESTORS (FII)
Index Futures
Long: — Short: —
Stock Futures
Long: — Short: —
Index Calls
Long: — Short: —
Index Puts
Long: — Short: —
DOMESTIC INSTITUTIONAL INVESTORS (DII)
Index Futures
Long: — Short: —
Stock Futures
Long: — Short: —
Note: DIIs primarily use Index Futures for hedging; options writing is limited compared to FIIs.
Data Matrices
Flow Heatmaps
Historical Charts
Documentation
FII 45-Day Flow Matrix
Visualizing sell-off density
Extreme Sell
Heavy Buy
DII 45-Day Flow Matrix
Domestic absorption pattern
Light Activity
Heavy Accumulation
Daily (Last 15)
Weekly (12W)
Monthly (24M)
Annual Tracker
Trading Date FII Gross Buy FII Gross Sell FII Net DII Gross Buy DII Gross Sell DII Net Total Liquidity
Week Ending FII Net DII Net Combined Liquidity Weekly Signal
Month & Year FII Net DII Net Net Money Flow Nifty Change
Calendar Year FII Equities Net DII Equities Net Total Flow DII Multiplier
Monthly Net Flows (Last 12m)
₹ Crore flows visualization
Multi-Year Cumulative Divergence
FII Extraction vs DII Injection
📊
FII & DII Data — User Manual
A fully open-source, institutional-grade terminal to track FII & DII flows in Indian equity markets.
Built by @Mr_Chartist — free for everyone to use, fork, and share.
✓ LIVE NSE SYNC ✓ 14-YEAR ARCHIVE ✓ MOBILE RESPONSIVE ✓ OPEN SOURCE
1
Live Sync Engine & Status

The terminal automatically fetches latest FII & DII data from NSE India on page load via CORS proxy integration, ensuring you always have access to the most current institutional flow data.

LIVE SYNC — Today's session data fetched successfully
LOCAL ARCHIVE — Using embedded historical data
🌐 Open Source — Use It, Fork It, Share It

This tool is completely free and open. No backend, no login, no subscription. Just open the HTML file and you have institutional-grade FII & DII analytics in your browser.

Follow @Mr_Chartist 📊 Version 6.0 — March 2026
error: Content is protected !!